| GR00057-A-1 | 11066 | NM_007020 | U1SNRNPBP | M-012359-00 | 0.57 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 11066 | NM_007020 | U1SNRNPBP | M-012359-00 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00149-A-1 | 11066 | 11066 | U1SNRNPBP | 44227 | 55.14 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 11066 | 11066 | U1SNRNPBP | 44227 | 55.6 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 11066 | 11066 | U1SNRNPBP | 44320 | 5.53 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 11066 | 11066 | U1SNRNPBP | 44320 | 7.58 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 11066 | 11066 | U1SNRNPBP | 44410 | 73.77 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 11066 | 11066 | U1SNRNPBP | 44410 | 54.4 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 11066 | 11066 | U1SNRNPBP | 128432 | -133.62 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 11066 | 11066 | U1SNRNPBP | 128432 | -64.19 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00180-A-1 | 11066 | 11066 | U1SNRNPBP | PL-50054 | 0.915 | none | | no | | Hepatitis C virus replication (1) | A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. | Tai et al. | 2009 | 19286138 | Cell line | Huh7/Rep-Feo | HCV replicon RNA copy number | Luminescence | siARRAY Human Genome siRNA Library | Genome-wide | siRNA | q-value | Complex criteria | | GR00184-A-1 | 11066 | NM_007020 | SNRNP35 | M-012359-00 | -0.707276697120747 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00197-A-1 | 11066 | 11066 | U1SNRNPBP | M-012359-00 | 0.704577513 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | GR00233-A-1 | 11066 | 11066 | U1SNRNPBP | np | np | Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection | | yes | siRNA pool validated | Hepatitis C virus (HCV) infection (1) | A genome-wide genetic screen for host factors required for hepatitis C virus propagation. | Li et al. | 2009 | 19717417 | Cell line | Huh7.5.1 | HCV core protein expression and DNA content after virus infection | Fluorescence | Human Genome siARRAY siRNA G-005000–05 | Genome-wide | siRNA | Percentage of infected cells | < | | GR00233-A-2 | 11066 | 11066 | U1SNRNPBP | D-012359-01 | 2.01 | Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after direct virus infection | | no | | Hepatitis C virus (HCV) infection (2) | A genome-wide genetic screen for host factors required for hepatitis C virus propagation. | Li et al. | 2009 | 19717417 | Cell line | Huh7.5.1 | HCV core protein expression and DNA content after direct virus infection | Fluorescence | siARRAY siRNA | Selected genes | siRNA | Normalized percentage of infected cells | < | | GR00233-A-2 | 11066 | 11066 | U1SNRNPBP | D-012359-04 | 1.33 | none | | no | | Hepatitis C virus (HCV) infection (2) | A genome-wide genetic screen for host factors required for hepatitis C virus propagation. | Li et al. | 2009 | 19717417 | Cell line | Huh7.5.1 | HCV core protein expression and DNA content after direct virus infection | Fluorescence | siARRAY siRNA | Selected genes | siRNA | Normalized percentage of infected cells | < | | GR00233-A-2 | 11066 | 11066 | U1SNRNPBP | D-012359-03 | 1.65 | Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after direct virus infection | | no | | Hepatitis C virus (HCV) infection (2) | A genome-wide genetic screen for host factors required for hepatitis C virus propagation. | Li et al. | 2009 | 19717417 | Cell line | Huh7.5.1 | HCV core protein expression and DNA content after direct virus infection | Fluorescence | siARRAY siRNA | Selected genes | siRNA | Normalized percentage of infected cells | < | | GR00233-A-2 | 11066 | 11066 | U1SNRNPBP | D-012359-02 | 0.8 | none | | no | | Hepatitis C virus (HCV) infection (2) | A genome-wide genetic screen for host factors required for hepatitis C virus propagation. | Li et al. | 2009 | 19717417 | Cell line | Huh7.5.1 | HCV core protein expression and DNA content after direct virus infection | Fluorescence | siARRAY siRNA | Selected genes | siRNA | Normalized percentage of infected cells | < | | GR00233-A-3 | 11066 | 11066 | U1SNRNPBP | D-012359-01 | 1.58 | Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection | | no | | Hepatitis C virus (HCV) infection (3) | A genome-wide genetic screen for host factors required for hepatitis C virus propagation. | Li et al. | 2009 | 19717417 | Cell line | Huh7.5.1 | HCV core protein expression and DNA content after viral supernatant infection | Fluorescence | siARRAY siRNA | Selected genes | siRNA | Normalized percentage of infected cells | < | | GR00233-A-3 | 11066 | 11066 | U1SNRNPBP | D-012359-04 | 0.67 | none | | no | | Hepatitis C virus (HCV) infection (3) | A genome-wide genetic screen for host factors required for hepatitis C virus propagation. | Li et al. | 2009 | 19717417 | Cell line | Huh7.5.1 | HCV core protein expression and DNA content after viral supernatant infection | Fluorescence | siARRAY siRNA | Selected genes | siRNA | Normalized percentage of infected cells | < | | GR00233-A-3 | 11066 | 11066 | U1SNRNPBP | D-012359-03 | 1.84 | Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection | | no | | Hepatitis C virus (HCV) infection (3) | A genome-wide genetic screen for host factors required for hepatitis C virus propagation. | Li et al. | 2009 | 19717417 | Cell line | Huh7.5.1 | HCV core protein expression and DNA content after viral supernatant infection | Fluorescence | siARRAY siRNA | Selected genes | siRNA | Normalized percentage of infected cells | < | | GR00233-A-3 | 11066 | 11066 | U1SNRNPBP | D-012359-02 | 0.55 | none | | no | | Hepatitis C virus (HCV) infection (3) | A genome-wide genetic screen for host factors required for hepatitis C virus propagation. | Li et al. | 2009 | 19717417 | Cell line | Huh7.5.1 | HCV core protein expression and DNA content after viral supernatant infection | Fluorescence | siARRAY siRNA | Selected genes | siRNA | Normalized percentage of infected cells | < | | GR00236-A-1 | 11066 | 11066 | U1SNRNPBP | M-012359-00 | 1.50429798892798 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | GR00240-S-1 | 11066 | NM_007020 | U1SNRNPBP | M-012359-00 | 0.03 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-2 | 11066 | NM_007020 | U1SNRNPBP | M-012359-00 | -0.8 | none | | no | Z-score -0.7125 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00249-S | 11066 | 11066 | U1SNRNPBP | J-012359-17 | -0.43252 | none | | no | number of cells compared to control (%): 87.08 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 11066 | 11066 | U1SNRNPBP | M-012359-01 | 1.32432 | Increased vaccinia virus (VACV) infection | | no | number of cells compared to control (%): 51.78 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 11066 | 11066 | SNRNP35 | s21806 | -0.52729 | none | | no | number of cells compared to control (%): 106.06 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 11066 | 11066 | SNRNP35 | s21807 | -1.56097 | Decreased vaccinia virus (VACV) infection | | no | number of cells compared to control (%): 95.93 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 11066 | 11066 | SNRNP35 | s21808 | 1.58532 | Increased vaccinia virus (VACV) infection | | no | number of cells compared to control (%): 99.08 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00250-A-1 | 11066 | 11066 | SNRNP35 | M-012359-00 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (1) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Genome-wide | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 11066 | 11066 | SNRNP35 | D-012359-01 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 11066 | 11066 | SNRNP35 | D-012359-02 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 11066 | 11066 | SNRNP35 | D-012359-03 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 11066 | 11066 | SNRNP35 | D-012359-04 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00255-A-1 | 11066 | 11066 | SNRNP35 | TRCN0000151897, TRCN0000152447, TRCN0000153513, TRCN0000156273, TRCN0000157288 | 0.377089195 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-1 | 11066 | 353116 | RILPL1 | TRCN0000159383, TRCN0000159472, TRCN0000159762, TRCN0000159828 | 0.089560248 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 11066 | 11066 | SNRNP35 | TRCN0000151897, TRCN0000152447, TRCN0000153513, TRCN0000156273, TRCN0000157288 | 0.334279048 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 11066 | 353116 | RILPL1 | TRCN0000159383, TRCN0000159472, TRCN0000159762, TRCN0000159828 | 0.170134581 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 11066 | 353116 | RILPL1 | TRCN0000159383, TRCN0000159472, TRCN0000159762, TRCN0000159828 | 0.567351783 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 11066 | 11066 | SNRNP35 | TRCN0000151897, TRCN0000152447, TRCN0000153513, TRCN0000156273, TRCN0000157288 | -0.149659521 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 11066 | 11066 | SNRNP35 | TRCN0000151897, TRCN0000152447, TRCN0000153513, TRCN0000156273, TRCN0000157288 | -1.544869088 | Negative genetic interaction between PTTG1-/- and PTTG1+/+ | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 11066 | 353116 | RILPL1 | TRCN0000159383, TRCN0000159472, TRCN0000159762, TRCN0000159828 | 0.378088337 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 11066 | 353116 | RILPL1 | TRCN0000159383, TRCN0000159472, TRCN0000159762, TRCN0000159828 | -0.265729239 | none | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 11066 | 11066 | SNRNP35 | TRCN0000151897, TRCN0000152447, TRCN0000153513, TRCN0000156273, TRCN0000157288 | -0.941692562 | Negative genetic interaction between KRASG13D/+ and KRAS+/- | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00300-A | 11066 | | SNRNP35 | TRCN0000152447, TRCN0000156273, TRCN0000153513, TRCN0000151897, TRCN0000157288 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00300-A | 11066 | | RILPL1 | TRCN0000159828, TRCN0000159472, TRCN0000159383, TRCN0000159762 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00302-A | 11066 | 11066 | U1SNRNPBP | TRCN0000156273, TRCN0000153513, TRCN0000151897 | -1.579 | Downregulation of RLR pathway after Sendai virus (SeV) infection | | | final hit | Antiviral innate immunity regulation | Genome-wide RNAi screen reveals a new role of a WNT/CTNNB1 signaling pathway as negative regulator of virus-induced innate immune responses. | Baril et al. | 2013 | 23785285 | Cell line | HEK293T | RLR pathway reporter | Luminescence | TRC shRNA Library | Selected genes | shRNA | Strictly standardized mean difference (SSMD) | < | Additional information about secondary screen. | GR00310-A-1 | 11066 | 11066 | U1SNRNPBP | np | 1.19 | none | | | | Sindbis virus (SINV) infection (1) | Genome-Wide RNAi Screen Identifies Novel Host Proteins Required for Alphavirus Entry | Ooi et al. | 2013 | 24367265 | Cell line | U2OS | Sindbis virus (SINV) reporter | Luminescence | Ambion Silencer V3 | Genome-wide | siRNA | Z-score | < -3 OR > 2 | | | 11066 | 11066 | U1SNRNPBP | np | -26.2 | Increased NF-kappaB reporter expression | | | 105% viability | | | | | | | | | | | | | | | | GR00368-A | 11066 | 11066 | SNRNP35 | | 0.66 | Decreased viability ratio | | | wt viability: 0,86 | Combinatorial effect with E-Cadherin | Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells | Telford et al. | 2015 | 25777964 | Cell line | MCF10A | Viability (synthetic lethal) | Luminescence | Dharmacon | Genome-wide | siRNA | CDH1(-/-)/wt viability ratio | < | MCF10A wild type viability higher-or-equal to 50% was considered as additional cutoff (values noted in "comment" section). | | 11066 | 11066 | SNRNP35 | | -0.03999999999999998 | none | | | | | | | | | | | | | | | | | | | GR00376-A-1 | 11066 | 11066 | SNRNP35 | | 0.287563813 | none | | | | Mitigators of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "high dose", ≈EC90, 13 ng/ml. Cutoff was derived from data submitted to Pubchem (ID 1117281). Reagent sequences but no ID | GR00376-A-2 | 11066 | 11066 | SNRNP35 | | 0.381159709 | none | | | | Sensitizers of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "low dose", ≈EC30, 3 ng/ml. Cutoff was derived from data submitted to PubChem (ID 1117281). Reagent sequences but no ID | GR00386-A-1 | 11066 | 11066 | U1SNRNPBP | | 121.884297520661 | Increased viability | | | | NOD2 stimulation by MDP | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | Viability | Luminescence | Dharmacon | Genome-wide | siRNA | Percentage growth | Decreased: <70, increased: >120 | Reagent IDs not provided | GR00386-A-2 | 11066 | 11066 | U1SNRNPBP | | -450.3 | Increased IL-8 secretion | | | | MDP-induced IL-8 secretion | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | IL-8 secretion | ELISA | Dharmacon | Genome-wide | siRNA | Percent inhibition of IL-8 secretion | Increased: <-300, Decreased: >60 | Concentration of IL-8 was measured from cell supernatants by sandwich ELISA. IL-8 values (pg/ml) were normalized to IL-8 secreted in cells treated with RIPK2-specific siRNA (100% inhibition) and non-targeting siRNA (0% inhibition). Secondary validating screen assessed 554 genes whose silencing affected MDP-induced IL-8 secretion in the primary screen. Final validated IL-8 regulators (positive or negative) are listed in the comments column. Reagent IDs not provided |